AU2011203740B2 - Methods and compositions for providing protective immunity in the elderly - Google Patents

Methods and compositions for providing protective immunity in the elderly Download PDF

Info

Publication number
AU2011203740B2
AU2011203740B2 AU2011203740A AU2011203740A AU2011203740B2 AU 2011203740 B2 AU2011203740 B2 AU 2011203740B2 AU 2011203740 A AU2011203740 A AU 2011203740A AU 2011203740 A AU2011203740 A AU 2011203740A AU 2011203740 B2 AU2011203740 B2 AU 2011203740B2
Authority
AU
Australia
Prior art keywords
dose
antigen
human
lag
years old
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011203740A
Other languages
English (en)
Other versions
AU2011203740A1 (en
Inventor
Robert S. Becker
Alan R. Shaw
N. David Taylor
Lynda G. Tussey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxinnate Corp
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of AU2011203740A1 publication Critical patent/AU2011203740A1/en
Application granted granted Critical
Publication of AU2011203740B2 publication Critical patent/AU2011203740B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2011203740A 2010-01-06 2011-01-05 Methods and compositions for providing protective immunity in the elderly Ceased AU2011203740B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29259310P 2010-01-06 2010-01-06
US61/292,593 2010-01-06
PCT/US2011/020159 WO2011084967A2 (en) 2010-01-06 2011-01-05 Methods and compositions for providing protective immunity in the elderly

Publications (2)

Publication Number Publication Date
AU2011203740A1 AU2011203740A1 (en) 2012-07-19
AU2011203740B2 true AU2011203740B2 (en) 2014-11-13

Family

ID=44306116

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011203740A Ceased AU2011203740B2 (en) 2010-01-06 2011-01-05 Methods and compositions for providing protective immunity in the elderly

Country Status (11)

Country Link
US (1) US20130095130A1 (enExample)
EP (1) EP2521563B1 (enExample)
JP (1) JP2013516469A (enExample)
KR (1) KR20120129893A (enExample)
CN (1) CN102740872A (enExample)
AU (1) AU2011203740B2 (enExample)
CA (1) CA2786306A1 (enExample)
MX (1) MX2012007916A (enExample)
SG (1) SG182305A1 (enExample)
WO (1) WO2011084967A2 (enExample)
ZA (1) ZA201205273B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
US8932598B2 (en) * 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
WO2009128949A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
US20090297552A1 (en) * 2008-04-25 2009-12-03 Aderem Alan A Flagellin polypeptide vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
JP5094407B2 (ja) * 2004-12-16 2012-12-12 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
WO2006069262A2 (en) * 2004-12-21 2006-06-29 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof
CA2596079A1 (en) * 2005-01-31 2006-08-10 Vaxinnate Corporation Novel polypeptide ligands for toll-like receptor 2 (tlr2)
PE20061428A1 (es) * 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
WO2009128949A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
US20090297552A1 (en) * 2008-04-25 2009-12-03 Aderem Alan A Flagellin polypeptide vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CUADROS C et al., Infection and Immunity, 2004, vol.72, no. 5, pages 2810-16 *
HULEATT et al., VACCINE, 2007, vol. 26, no. 2, pages 201-214 *
PODDA et al., Vaccine, 2001, vol. 19, no. 17-19, pages 2673-80 *
WANG BAO-ZHONG et al., Journal of Virology 2008, vol. 82, no. 23, pages 11813-23 *

Also Published As

Publication number Publication date
EP2521563A4 (en) 2013-07-24
EP2521563A2 (en) 2012-11-14
CN102740872A (zh) 2012-10-17
SG182305A1 (en) 2012-08-30
JP2013516469A (ja) 2013-05-13
EP2521563B1 (en) 2016-12-07
CA2786306A1 (en) 2011-07-14
US20130095130A1 (en) 2013-04-18
AU2011203740A1 (en) 2012-07-19
MX2012007916A (es) 2012-11-06
ZA201205273B (en) 2013-09-25
WO2011084967A3 (en) 2011-11-10
KR20120129893A (ko) 2012-11-28
WO2011084967A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
JP6062245B2 (ja) 組換えｒｓｖ抗原
Jegerlehner et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses
JP6069295B2 (ja) 免疫組成物、免疫組成物の製造方法、疾患の治療剤または予防剤、組み替えポリペプチド、核酸配列、ベクターおよび宿主細胞
Zheng et al. Development of universal influenza vaccines based on influenza virus M and NP genes
CN103957891B (zh) 基于流感血凝素蛋白的新颖疫苗
US20150329597A1 (en) Rsv f prefusion trimers
US20150099859A1 (en) Deletion Mutants of Flagellin and Methods of Use
US6558673B1 (en) Complexes of immunogens derived from RSV surface glycoprotein G covalently coupled to a support molecule
JP2012530761A (ja) ワクチン
US20150093406A1 (en) Modified Coiled Coil Type Proteins having Improved Properties
KR20230107621A (ko) 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
EP2521563B1 (en) Compositions for providing protective immunity in the elderly
CN107108755A (zh) 通过融合到来自七鳃鳗的序列进行的重组蛋白多聚化
EP0176493B1 (en) Vaccinal polypeptides
CA3235138A1 (en) Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing
CN115850395B (zh) 一种流感病毒通用型纳米颗粒疫苗及其制备方法
WO2024036193A2 (en) Rabies g protein and uses thereof
HUT54732A (en) Process for producing vaccine polypeptides
RU2757013C2 (ru) Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения
WO2025006263A2 (en) Design of universal influenza vaccine candidates via antigen reorientation
KR20250046320A (ko) 계절성 및 신종 감염의 치료 및 예방을 위한 백신
CN102174089B (zh) 一种禽流感病毒头部蛋白及其制备方法和应用
WO2021188804A1 (en) Bacteriophage-based vaccines and engineered bacteriophage
WO2020034048A2 (es) Vacuna contra el síndrome cardiopulmonar causado por hantavirus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired